Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.

[1]  Total synthesis of (+/-)-discretamine and (+/-)-stepholidine. , 1977, The Journal of organic chemistry.

[2]  A new synthesis of benzocyclobutenes. Thermal and electron impact induced decomposition of 3-isochromanones , 1978 .

[3]  H. E. Rosvold,et al.  Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. , 1979, Science.

[4]  Synthesis of racemic thalictricavine berlambine and racemic canadine from a common intermediate , 1979 .

[5]  Synthesis of (.+-.)-thalictricavine, berlambine, and (.+-.)-canadine from a common intermediate , 1979 .

[6]  A. Grace,et al.  Nigral dopamine neurons: intracellular recording and identification with L-dopa injection and histofluorescence. , 1980, Science.

[7]  A. Grace,et al.  Intracellular and extracellular electrophysiology of nigral dopaminergic neurons—1. Identification and characterization , 1983, Neuroscience.

[8]  A. Grace,et al.  The control of firing pattern in nigral dopamine neurons: burst firing , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[9]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[10]  N. Kaur,et al.  Facile generation and trapping of α-oxo-o-quinodimethanes : synthesis of 3-aryl-3,4-dihydroisocoumarins and protoberberines , 1992 .

[11]  N. Swerdlow,et al.  Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. , 1994, The Journal of pharmacology and experimental therapeutics.

[12]  H. Schäfer,et al.  SYNTHESIS OF THE SALUTARIDINE AND APORPHINE SKELETON VIA PALLADIUM(0) CATALYZED CYCLIZATION AND SRN1 REACTION OF 2'-BROMORETICULINES , 1995 .

[13]  T. Ikariya,et al.  Asymmetric Transfer Hydrogenation of Aromatic Ketones Catalyzed by Chiral Ruthenium(II) Complexes , 1995 .

[14]  P. Goldman-Rakic,et al.  Modulation of memory fields by dopamine Dl receptors in prefrontal cortex , 1995, Nature.

[15]  B. Peeters,et al.  Prospects for improved antidepressants. , 1995, Journal of medicinal chemistry.

[16]  I. Ziv,et al.  Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. , 1996, Advances in neurology.

[17]  A. Meyers,et al.  Total Synthesis of (-)-Tetrahydropalmatine via Chiral Formamidine Carbanions: Unexpected Behavior with Certain Ortho-Substituted Electrophiles. , 1996, The Journal of organic chemistry.

[18]  U. Spampinato,et al.  8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release , 1997, Psychopharmacology.

[19]  M. Iyo,et al.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.

[20]  Dioxirane Epoxidation of 10-Membered-Ring Stilbene Lactams as Synthetic Precursors to Protoberberines. , 1999, The Journal of organic chemistry.

[21]  M. Pistis,et al.  Dissociation of Haloperidol, Clozapine, and Olanzapine Effects on Electrical Activity of Mesocortical Dopamine Neurons and Dopamine Release in the Prefrontal Cortex , 2000, Neuropsychopharmacology.

[22]  F. Kasten.  Early Mouse Models of Human Diseases , 2000, Science.

[23]  T. Chase,et al.  Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models , 2001, Neurology.

[24]  Yu Fu,et al.  (-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions. , 2002, Trends in pharmacological sciences.

[25]  Asymmetric synthesis of the protoberberine alkaloid (S)-(-)-xylopinine using enantiopure sulfinimines. , 2002, The Journal of organic chemistry.

[26]  C. Altar,et al.  The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. , 2002, European journal of pharmacology.

[27]  R. V. Van Heertum,et al.  Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia , 2002, The Journal of Neuroscience.

[28]  T. Sharma,et al.  Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics , 2002, Schizophrenia Research.

[29]  Stephen M Stahl,et al.  Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. , 2003, The Journal of clinical psychiatry.

[30]  R. Mailman,et al.  Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.

[31]  A. Chocyk,et al.  Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex , 2003, Brain Research.

[32]  D. Marona-Lewicka,et al.  Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats , 2004, Psychopharmacology.

[33]  J. Bolam,et al.  Uniform Inhibition of Dopamine Neurons in the Ventral Tegmental Area by Aversive Stimuli , 2004, Science.

[34]  Anissa Abi-Dargham,et al.  Do we still believe in the dopamine hypothesis? New data bring new evidence. , 2004, The international journal of neuropsychopharmacology.

[35]  P. Celada,et al.  Involvement of 5-HT1A Receptors in Prefrontal Cortex in the Modulation of Dopaminergic Activity: Role in Atypical Antipsychotic Action , 2005, The Journal of Neuroscience.

[36]  A. Newman-Tancredi,et al.  Contrasting Contribution of 5-Hydroxytryptamine 1A Receptor Activation to Neurochemical Profile of Novel Antipsychotics: Frontocortical Dopamine and Hippocampal Serotonin Release in Rat Brain , 2005, Journal of Pharmacology and Experimental Therapeutics.

[37]  Paul Chen,et al.  Serotonin 5-HT1A Receptors Regulate NMDA Receptor Channels through a Microtubule-Dependent Mechanism , 2005, The Journal of Neuroscience.

[38]  L. Pilowsky,et al.  The place of partial agonism in psychiatry: recent developments , 2005, Journal of psychopharmacology.

[39]  A. Newman-Tancredi,et al.  Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. , 2005, The international journal of neuropsychopharmacology.

[40]  D. Jackson,et al.  The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat , 1994, Psychopharmacology.

[41]  Ruoyan Chen,et al.  Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies , 2007, Psychopharmacology.

[42]  N. Leadbeater,et al.  Direct conversion of aryl halides to phenols using high-temperature or near-critical water and microwave heating , 2006 .

[43]  Sarizotan hydrochloride : Antidyskinetic drug 5-HT1A receptor agonist dopamine D2 receptor ligand , 2006 .

[44]  Wei Wang,et al.  The effect of l-stepholidine, a novel extract of Chinese herb, on the acquisition, expression, maintenance, and re-acquisition of morphine conditioned place preference in rats , 2007, Neuropharmacology.

[45]  S. Laviolette.  Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia? , 2007, Schizophrenia bulletin.

[46]  M. Gao,et al.  l-Stepholidine increases the frequency of sEPSC via the activation of D1 dopamine signaling pathway in rat prelimbic cortical neurons , 2007, Acta Pharmacologica Sinica.

[47]  B. Bunney,et al.  Clozapine Blocks D-Amphetamine-Induced Excitation of Dopamine Neurons in the Ventral Tegmental Area , 2007, Neuropsychopharmacology.

[48]  Xuechu Zhen,et al.  Recent developments in studies of l-stepholidine and its analogs: chemistry, pharmacology and clinical implications. , 2007, Current medicinal chemistry.

[49]  Shitij Kapur,et al.  Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. , 2007, The American journal of psychiatry.

[50]  Xuechu Zhen,et al.  N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. , 2008, Bioorganic & medicinal chemistry.

[51]  Fumitoshi Kodaka,et al.  Differential Contributions of Prefrontal and Hippocampal Dopamine D1 and D2 Receptors in Human Cognitive Functions , 2008, The Journal of Neuroscience.

[52]  Xuechu Zhen,et al.  Estrogen regulates responses of dopamine neurons in the ventral tegmental area to cocaine , 2008, Psychopharmacology.

[53]  Xuechu Zhen,et al.  Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. , 2008, Bioorganic & medicinal chemistry.

[54]  Xuechu Zhen,et al.  Single dose of morphine produced a prolonged effect on dopamine neuron activities , 2008, Molecular pain.

[55]  A very simple copper-catalyzed synthesis of phenols employing hydroxide salts. , 2009, Angewandte Chemie.

[56]  Xuechu Zhen,et al.  Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand , 2009, Schizophrenia Research.

[57]  Jianjun Cheng,et al.  Enantioselective total synthesis of (-)-(S)-stepholidine. , 2009, The Journal of organic chemistry.

[58]  Dongbing Zhao,et al.  Synthesis of phenol, aromatic ether, and benzofuran derivatives by copper-catalyzed hydroxylation of aryl halides. , 2009, Angewandte Chemie.

[59]  O. Baudoin,et al.  Synthesis of 3,4-dihydroisoquinolines by a C(sp3)-H activation/electrocyclization strategy: total synthesis of coralydine. , 2009, Angewandte Chemie.

[60]  Xuechu Zhen,et al.  Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist. , 2010, Journal of medicinal chemistry.

[61]  P. Barone,et al.  Neurotransmission in Parkinson’s disease: beyond dopamine , 2010, European journal of neurology.

[62]  Xuechu Zhen,et al.  l-Stepholidine reduced l-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease , 2010, Neurobiology of Aging.

[63]  C. Beyer,et al.  Innovative approaches for the development of antidepressant drugs: Current and future strategies , 2005, NeuroRX.

[64]  R. Baldessarini,et al.  Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. , 2013, Chemical reviews.